BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231127
DTEND;VALUE=DATE:20231201
DTSTAMP:20260516T075557
CREATED:20230803T103428Z
LAST-MODIFIED:20230803T103428Z
UID:37560-1701043200-1701388799@www.pharmajournalist.com
SUMMARY:5th Annual Gene Therapy Analytical Development Summit 2023
DESCRIPTION:Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy\, robust and detailed analytics are the cornerstone of gene therapy development. As regulators scrutinize products more closely\, accurately characterizing gene therapy products and standing behind safety and efficacy is crucial to drug developers bringing gene therapies into and through the clinic. \nIn this context\, the 5th Annual Gene Therapy Analytical Development is returning in 2023\, uniting 400+ analytical experts to explore how the latest analytical methods are being developed and applied to guarantee the quality\, consistency\, safety\, and efficacy of gene therapy products. \nJoin biopharma colleagues specializing in bioassays\, molecular biology\, physicochemical properties\, quality\, process development and regulation across 4 days of niche\, expert presentations\, and dedicated networking opportunities. This is your must-attend meeting to collaborate ideas\, success and challenges to capitalize on the technological advances in analytical development to reach the ultimate goal of bringing safer\, efficacious therapies to patients more quickly and effectively. \nTo know more visit: https://ter.li/qf50s3
URL:https://www.pharmajournalist.com/event/5th-annual-gene-therapy-analytical-development-summit-2023/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231127
DTEND;VALUE=DATE:20231130
DTSTAMP:20260516T075557
CREATED:20230925T125234Z
LAST-MODIFIED:20230925T125234Z
UID:37847-1701043200-1701302399@www.pharmajournalist.com
SUMMARY:7th Obesity & NASH Drug Development Summit
DESCRIPTION:Eli Lilly’s ‘triple G’ drug retatrutide has galvanized the metabolic field to boost investment in the game-changing obesity drug revolution. With up to 24% weight loss\, a new record for the obesity field has been set and the time to get ahead of the curve is now. In parallel\, we’re witnessing history being made with the world’s first approved NASH treatment potentially being right around the corner with Madrigal’s THR β-selective agonist\, marking this year a pivotal time for the metabolic field to forever elevate the approach towards drug development and overcome regulatory barriers. \nReuniting metabolic experts to enable the assessment of the competitive landscape\, the 7th Obesity & NASH Drug Development Summit is uniquely positioned to capture all the latest breakthroughs and research you need to join the race and commercialize your GLP-1 RAs\, tri-agonists\, dual agonists\, tetra-specific drugs\, glucocorticoid receptor modulators and more. \n2023 is an exciting year due to the evolution in digital pathology\, artificial intelligence\, omics\, multifunctional molecules\, non-invasive biomarkers\, target discovery and liver models\, this is your timely meeting dedicated to bringing the metabolic community closer to navigate the route to even more approvals. However\, as industry gets closer to successes\, challenges remain. \nKeen to overcome these discovery\, regulatory\, clinical\, and commercial hurdles? \nJoin 160+ experts at the largest gathering of obesity and NASH industry drug developers from Eli Lilly\, Novo Nordisk\, Madrigal\, Akero\, Gilead\, Pfizer\, AstraZeneca\, Gilead\, Inventiva and many more to cultivate sustainable weight-loss drugs and navigate the route towards the first approval in NASH. Don’t miss your opportunity to hear from 42+ metabolic experts over 3 jam-packed days with all the latest end-to-end updates to advance your drug development. \nTo know more visit: https://bit.ly/465Aa3m
URL:https://www.pharmajournalist.com/event/7th-obesity-nash-drug-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR